Familial partial lipodystrophy presenting as metabolic syndrome

Area of Science:

• Genetics and Molecular Biology
• Endocrinology
• Metabolic Disorders

Background:

• Familial partial lipodystrophy type 2 (FPLD2) is a rare genetic disorder characterized by lipodystrophy and metabolic complications.
• The LMNA gene encodes lamins, crucial structural proteins in the nuclear envelope, and mutations are linked to various lipodystrophic syndromes.

Observation:

• A patient presented with clinical features consistent with FPLD2, exhibiting a heterozygous p.R545H missense mutation in the LMNA gene.
• The patient's initial presentation mimicked metabolic syndrome, underscoring the diagnostic challenge and overlap between these conditions.

Findings:

• The identified LMNA mutation (c.1634 G > A) is associated with a spectrum of metabolic derangements, including type 2 diabetes mellitus, fatty liver disease, polycystic ovarian syndrome, and hypertriglyceridemia.
• This mutation was previously noted in a heart failure database, suggesting a potential link between FPLD2 and cardiovascular complications.

Implications:

• Early identification of FPLD2 is crucial for managing associated metabolic and potentially cardiac conditions.
• Understanding the genotype-phenotype correlation of LMNA mutations can improve diagnostic accuracy and patient care strategies.
• Further research into the pathogenic mechanisms linking LMNA mutations to metabolic syndrome and heart failure is warranted.